Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients-Reference-Cited by-同舟云学术

Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients

Published:2019-03-31 Issue:6 Volume:85 Page:1283-1289
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Iacovelli Roberto¹²^ORCID,Ciccarese Chiara¹²,Fornarini Giuseppe³,Massari Francesco⁴,Bimbatti Davide¹,Mosillo Claudia¹,Rebuzzi Sara Elena³,Di Nunno Vincenzo⁴,Grassi Massimiliano³,Fantinel Emanuela¹,Ardizzoni Andrea⁴,Tortora Giampaolo¹²

Affiliation:

1. Department of Medical OncologyAzienda Ospedaliera Universitaria Integrata (AOUI) Verona Italy

2. Oncologia MedicaFondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy

3. Department of Medical OncologyIRCCS Azienda Ospedaliera Universitaria San Martino‐Istituto Nazionale per la Ricerca sul Cancro Genova Italy

4. Department of Medical OncologySant'Orsola‐Malpighi Hospital Bologna Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13895

Reference22 articles.

1. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

3. Progression‐free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC);Choueiri TK;Ann Oncol,2017

4. Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

5. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report;Cardiovascular Toxicology;2024-07-31

2. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis;Expert Review of Anticancer Therapy;2024-06-16

3. Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology;Cancer Innovation;2024-02-05

4. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence;Clinical Genitourinary Cancer;2023-11

5. The cardiovascular burden of renal cell carcinoma;International Journal of Cardiology;2023-08